Doctors are always looking for new uses for existing drugs. What started out as a medication for a very serious eye problem is now making waves as the latest thing in cosmetics. It can make eyelashes longer & thicker.
Latisse contains bimatoprost, a compound from a glaucoma drug called Lumigan. It binds to receptors in the eyelashes that may be involved in the development and re-growth of hair follicles. Allergan has used bimatoprost since 2001 in Lumigan.
The company began studying the potential of using a lower dose of topical bimatoprost to stimulate eyelash growth after Lumigan users developed unusually lush lashes. It's specifically being marketed as a once-a-day medication to treat eyelash hypotrichosis, or lack of hair growth.
Latisse pushes more follicles into the growth phase, and lengthens the time they spend there. But you do need to be careful applying Latisse.
If it gets on other skin, it can cause discoloration.
And some users in the trial reported redness, or itching of the eyes.
The drug's effect isn't immediate. According to manufacturer Allergan, the drug usually brings results two to four months after users start it.
Latisse has been on the market for about two weeks now... And it's generated a lot of interest.
But it isn't cheap. It costs about $240 dollars for a year's supply. And you have to keep using it to keep your lashes full.
It's possible that the drug may also spur eyebrow and scalp hair growth, doctors told the Wall Street Journal. But Allergan spokesperson Heather Katt says the company hasn't explored using Latisse for those purposes
Friday, February 27, 2009
Friday, February 20, 2009
One of the main complaints that patients have had with the Alcon ReStor Intraocular Lens was the close working distance and poor intermediate vision found with this lens. The near focal point of this implant is around 13 inches which forced patients to hold reading material much closer than they may have been accustomed to. This lens also did not perform well at the computer or when used for other intermediate tasks such as looking at prices on store shelves etc. Alcon has addressed these problems with a new model ReStor which has a near focal length of approximately 16 inches. In the recent FDA clinical trial of the AcrySof IQ Restor IOL +3.0 D (Alcon Laboratories, Inc., Fort Worth, TX), patients achieved the same superb distance and near vision with this lens as those who received the AcrySof IQ Restor +4.0 D lens (Alcon Laboratories, Inc.). As an added benefit, compared with the +4.0 D model, the +3.0 D design dramatically improved patients' intermediate vision at 50, 60, and 70 cm .
Thursday, February 5, 2009
Keratoconus is a corneal disorder in which progressive astigmatism develops, probably because of weakening. Patients who suffer from keratoconus suffer from corneal thinning and vision loss. Ultimately patients may require a corneal transplant. Recently, surgeons have begun to implant plastic inserts (Intacs) to bolster the cornea and delay, perhaps indefinitely, the need for a corneal transplant. I have implanted Intacs in several keratoconus patients and have been impressed with the results. Patients have exhibited a reversal in their astigmatism and often show an improvement in best corrected vision. the original application for Intacs was for the correction of nearsightedness. Popularity has waned as the LASIK procedure improved but Intacs have enjoyed a resurrgence in interest for their use in keratoconus. For more information go to www.intacsforkeratoconus.com.